Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History & Milestones
  • Products
    • Product Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
MENU Close

2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046

2021/05/10 ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED), Application No.3,033,046

  • Post author:alarpharm
  • Post published:8 . 6 . 2021
  • Post category:Media releases

You Might Also Like

2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582

6 . 12 . 2022

2021/04/12 ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) (Application No. 2019102895).

21 . 4 . 2021

2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.

13 . 4 . 2021

2022/12/29 ALA -1300 Received notice of patent allowance from the Mexican Institute of Industrial Property (IMPI), NO: MX/a/2020/008471

1 . 2 . 2023

2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

10 . 3 . 2021
  • News
  • Events
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History & Milestones
  • Company Profile
  • Leadership Team
  • History & Milestones

PRODUCTS

  • Product Pipeline
  • Contract Manufacturing
  • Product Pipeline
  • Contract Manufacturing

MEDIA

  • News
  • Events
  • News
  • Events

INVESTORS

  • Stock Info
  • Financials
  • Stock Info
  • Financials

CONTACT US

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
    • Contact Us
×

Cart